Alexandria Venture Investments
Alexandria Venture Investments is a venture capital firm that develops the work in real estate technology, and healthcare sectors.
Business Model:
Revenue: $2.6B
Employees: 501-1,000
Rankings
Industries / Tags:
Detailed Alexandria Venture Investments Information
Geographic Data
Address: 26 North Euclid Avenue
City: Pasadena
State: CA
Zip: 91101
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$5B
Social
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company&s;s strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that are developing transformative new modalities and platforms to meaningfully improve human health.
Contact Phone:
+16265780777
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 10/2021 | Mozart Therapeutics | Series A | 0 |
| 2/2018 | Kallyope | Series B | 66M |
| 2/2018 | Moderna Therapeutics | Series G | 0 |
| 10/2021 | Deka Biosciences | Series A | 0 |
| 7/2020 | Vesigen Therapeutics | Series A | 28.5M |
| 12/2017 | Obsidian Therapeutics | Series A | 0 |
| 9/2021 | Acrigen Biosciences | Seed Round | - |
| 10/2019 | Adaptive Phage Therapeutics | Venture Round | 7M |
| 3/2018 | Prevail Therapeutics | Series A | 75M |
| 10/2018 | Inspirna, Inc.(formerly Rgenix, Inc.) | Series C | 40M |
| 6/2022 | Dren Bio | Series B | 0 |
| 1/2022 | Avalo | Convertible Note | 750k |
| 10/2018 | Stoke Therapeutics | Series B | 90M |
| 7/2020 | Vor Biopharma | Series B | 0 |
| 4/2021 | Alloy Therapeutics | Series C | 75M |
| 7/2019 | X-Vax Technology | Series A | 0 |
| 4/2021 | SeQure DX | Series A | 0 |
| 12/2021 | Meiogenix | Series A | 12.4M |
| 1/2021 | Myeloid Therapeutics | Series A | 50M |
| 1/2019 | Frequency Therapeutics | Series B | - |
| 1/2021 | Encodia | Series C | 75M |
| 7/2021 | Wugen | Series B | 0 |
| 9/2022 | Novome | Series B | 0 |
| 9/2018 | Epic Sciences | Series E | 0 |
| 4/2017 | Arsanis | Series D | 0 |
| 3/2018 | IDEAYA Biosciences | Series B | 0 |
| 10/2019 | Molecular Assemblies | Series A | 0 |
| 1/2019 | Immusoft | Series B | 0 |
| 5/2022 | Pleno | Seed Round | 0 |
| 10/2022 | Odyssey Therapeutics | Series B | 0 |
| 3/2022 | Umaro Foods | Seed Round | 0 |
| 1/2020 | TwinStrand Biosciences | Series A | 16M |
| 4/2022 | Pheast Therapeutics | Series A | 0 |
| 10/2021 | Immunai | Series B | 215M |
| 3/2022 | Eclipse Bioinnovations | Series A | 14M |
| 8/2021 | Humacyte | PIPE | 175M |
| 10/2021 | Crop Enhancement | Convertible Note | - |
| 5/2021 | Inari | Series D | 0 |
| 9/2021 | LEXEO Therapeutics | Series B | 0 |
| 12/2017 | Aura Biosciences | Series C | 0 |
| 1/2020 | Novome Biotechnologies | Series A | 0 |
| 6/2021 | TRex Bio | Series A | 59M |
| 5/2021 | Invaio Sciences | Series C | 88.9M |
| 3/2019 | Cardea Bio | Series A | 7.8M |
| 9/2021 | Kytopen | Series A | 0 |
| 9/2018 | BlueLight Therapeutics | Series C | 20M |
| 4/2023 | Function Oncology | Series A | 28M |
| 9/2022 | Tavros Therapeutics | Seed Round | 7.5M |
| 8/2021 | Immunitas Therapeutics | Series B | 0 |
| 9/2020 | Korro Bio | Series A | 0 |
| 5/2018 | Celsius Therapeutics | Series A | 65M |
| 11/2021 | Parthenon Therapeutics | Series A | 0 |
| 12/2018 | Kallyope | Series B | 21M |
| 12/2019 | Aspen Neuroscience | Seed Round | 0 |
| 8/2018 | Inari | Series B | 40M |
| 7/2022 | Cartography Biosciences | Series A | 0 |
| 7/2022 | Ozette Technologies | Series A | 0 |
| 6/2019 | Encoded Therapeutics | Series C | 104M |
| 11/2022 | Haystack Oncology | Series A | 56M |
| 12/2020 | Faze Medicines | Series A | 81M |
| 7/2021 | Axonis Therapeutics, Inc. | Venture Round | 0 |
| 2/2022 | Harpe Bio | Venture Round | 3M |
| 2/2022 | Harpe Bio | Convertible Note | 3.2M |
| 3/2019 | Gencove | Seed Round | 3M |
| 9/2021 | Jasper Therapeutics | Post-IPO Equity | 0 |
| 6/2021 | Bright Peak Therapeutics | Series B | 107M |
| 1/2021 | LEXEO Therapeutics | Series A | 0 |
| 7/2021 | Deep Genomics | Series C | 0 |
| 8/2021 | Thryv Therapeutics | Series A | 0 |
| 3/2017 | Boragen | Series A | 10M |
| 2/2023 | Paratus Sciences | Series A | 0 |
| 7/2017 | Rodeo Therapeutics | Series A | 5.9M |
| 3/2017 | EGenesis | Series A | 0 |
| 6/2021 | ImmuneID | Series A | 0 |
| 3/2019 | Karuna Therapeutics | Series B | 0 |
| 6/2020 | Autobahn Therapeutics | Series B | 76M |
| 4/2023 | Orbital Therapeutics | Series A | 0 |
| 11/2021 | Fountain Therapeutics | Series A | 0 |
| 7/2018 | Compass Therapeutics, Inc. | Series A | 0 |
| 3/2020 | Kallyope | Series C | 112M |
| 12/2022 | SonoThera | Series A | 0 |
| 11/2018 | Caraway Therapeutics | Series A | 23M |
| 11/2021 | Nitrase Therapeutics | Series A | 0 |
| 10/2017 | Visterra | Series C | 0 |
| 5/2018 | Insitro | Series A | 100M |
| 5/2022 | Remix Therapeutics | Series B | 0 |
| 9/2017 | LifeMine Therapeutics | Series A | 0 |
| 11/2021 | GeneCentric Therapeutics | Series B | 0 |
| 6/2018 | StrideBio | Series A | 15.7M |
| 5/2023 | Ten63 Therapeutics | Series A | 0 |
| 12/2019 | Jasper Therapeutics | Series A | 35M |
| 6/2018 | Precision BioSciences | Series B | 0 |
| 7/2017 | Evelo Biosciences | Series B | 50M |
| 10/2017 | Cydan | Venture Round | 34M |
| 7/2021 | IgGenix | Series A | 0 |
| 7/2019 | GNS Healthcare | Series D | 23M |
| 9/2020 | Sonoma Pharmaceuticals | Post-IPO Equity | 70M |
| 3/2022 | Creyon Bio | Series A | 0 |
| 9/2018 | MouSensor | Seed Round | 3.3M |
| 9/2018 | OncoResponse | Series B | 40M |
| 6/2020 | Element Biosciences | Series B | 30M |
| 2/2019 | Applied Therapeutics | Series B | 0 |
| 1/2019 | Dewpoint Therapeutics | Series A | 60M |
| 1/2021 | AltPep | Series A | 23.1M |
| 6/2023 | AltPep | Series B | 0 |
| 10/2022 | Matchpoint Therapeutics | Series A | 70M |
| 11/2017 | Codiak Biosciences | Series C | 76.5M |
| 4/2021 | Molecular Assemblies | Series A | 0 |
| 10/2019 | Verseau Therapeutics | Equity | 50M |
| 1/2017 | Halio | Series C | 65M |
| 12/2020 | Remix Therapeutics | Series A | 65M |
| 4/2021 | Ventus Therapeutics | Series B | 100M |
| 11/2019 | Genetron Health | Series D | 71M |
| 4/2018 | QurAlis | Seed Round | - |
| 9/2018 | ENB Therapeutics | Series A | 8.1M |
| 5/2018 | Nohla Therapeutics | Series B | 45M |
| 1/2023 | Melonfrost | Seed Round | 7M |
| 2/2017 | Applied Therapeutics | Series A | 6.1M |
| 5/2021 | Marvin | Seed Round | 0 |
| 7/2020 | Compass Therapeutics, Inc. | Venture Round | 0 |
| 2/2023 | Garuda Therapeutics | Series B | 0 |
| 11/2019 | miRecule | Seed Round | 0 |
| 10/2021 | IpiNovyx Bio | Seed Round | 0 |
| 5/2021 | miRecule | Venture Round | 0 |
| 10/2021 | Soli Organic | Venture Round | 0 |
| 1/2019 | Greenlight Biosciences | Venture Round | 50M |
| 9/2020 | Sonoma BioTherapeutics | Series A | 0 |
| 9/2019 | Boundless Bio | Series A | 46.4M |
| 3/2022 | Affini-T Therapeutics | Venture Round | 0 |
| 10/2021 | DNA Script | Series C | 0 |
| 3/2017 | Antiva Biosciences | Series C | 22M |
| 7/2020 | Frequency Therapeutics | Post-IPO Equity | 42.3M |
| 9/2018 | Silverback Therapeutics | Series A | 37.5M |
| 11/2018 | Ribometrix | Series A | 30M |
| 11/2022 | Cajal Neuroscience | Series A | 96M |
| 1/2018 | Skyhawk Therapeutics | Seed Round | 8M |
| 5/2021 | TwinStrand Biosciences | Series B | 50M |
| 6/2018 | Cibus | Series C | 70M |
| 12/2021 | Ambys Medicines | Series A | 47M |
| 4/2020 | Nitrase Therapeutics | Series A | 38M |
| 6/2021 | Senda Biosciences | Series B | 0 |
| 4/2019 | Insitro | Series A | 100M |
| 9/2021 | Disc Medicine | Post-IPO Equity | 0 |
| 9/2021 | Disc Medicine | Series B | 90M |
| 2/2021 | Ensoma | Series A | 0 |
| 9/2021 | Asher Bio | Series B | 0 |
| 3/2019 | Imara | Series B | 0 |
| 1/2018 | Expansion Therapeutics | Series A | 55.3M |
| 3/2019 | Prevail Therapeutics | Series B | 50M |
| 9/2022 | Capstan Therapeutics | Series A | 102M |
| 6/2021 | Mnemo Therapeutics | Series A | 90M |
| 10/2019 | Variant Bio | Series A | 24.7M |
| 9/2021 | Lycia Therapeutics | Series B | 70M |
| 5/2022 | MOMA Therapeutics | Series B | 0 |
| 9/2021 | ROME Therapeutics | Series B | 0 |
| 8/2018 | Magnolia NeuroSciences | Series A | 0 |
| 4/2019 | Arrakis Therapeutics | Series B | 75M |
| 6/2021 | Veralox Therapeutics | Series A | 0 |
| 7/2018 | ORIG3N | Series B | 0 |
| 5/2023 | Myeloid Therapeutics | Series B | 0 |
| 7/2018 | Antiva Biosciences | Series C | 15M |
| 12/2020 | Vigil Neuroscience | Series A | 50M |
| 5/2023 | Myeloid Therapeutics | Series A | 0 |
| 6/2021 | Neurona Therapeutics | Venture Round | 0 |
| 5/2021 | BioTheryX | Series E | 92M |
| 10/2020 | Dren Bio | Series A | 0 |
| 10/2017 | Ribometrix | Seed Round | 7.5M |
| 1/2021 | Blacksmith Medicines | Seed Round | - |
| 5/2021 | Soteria Biotherapeutics | Series A | 42M |
| 5/2021 | Advanced Animal Diagnostics | Series E | 0 |
| 8/2022 | Senda Biosciences | Series C | 123M |
| 3/2021 | StrideBio | Series B | 0 |
| 3/2020 | Redpin Therapeutics | Series A | 15.5M |
| 1/2023 | Ensoma | Series B | 0 |
| 7/2017 | Compass Therapeutics, Inc. | Series A | - |
| 3/2018 | TCR2 | Series B | 0 |
| 8/2021 | Sonoma BioTherapeutics | Series B | 0 |
| 12/2017 | Metacrine | Series B | 22M |
| 3/2022 | TRex Bio | Series A | 0 |
| 1/2021 | Dice Therapeutics | Series C | 80M |
| 2/2022 | Kallyope | Series D | 0 |
| 11/2021 | Acrivon Therapeutics | Series B | 0 |
| 5/2022 | Aspen Neuroscience | Series B | 0 |
| 2/2018 | Quentis | Series A | 48M |
| 1/2022 | Korro Bio | Series B | 0 |
| 1/2021 | Senti Biosciences | Series B | 105M |
| 12/2021 | NextVivo | Venture Round | 7.9M |
| 12/2022 | Dantari | Series A | 0 |
| 2/2022 | Ventus Therapeutics | Series C | 0 |
| 12/2020 | RayzeBio | Series B | 105M |
| 6/2023 | Bitterroot Bio | Series A | 0 |
| 1/2019 | Tiburio Therapeutics | Series A | 31M |
| 3/2020 | Affinia Therapeutics | Series A | 0 |
| 6/2022 | DEM BioPharma | Series A | 0 |
| 8/2021 | Effector Therapeutics | Post-IPO Equity | 0 |
| 7/2017 | Effector Therapeutics | Series C | 38.6M |
| 9/2018 | Benson Hill | Series C | 65M |
| 9/2017 | Gritstone Bio | Series B | 93M |
| 3/2022 | Celsius Therapeutics | Series B | 0 |
| 10/2021 | Neumora Therapeutics | Series A | 0 |
| 12/2019 | ImCheck Therapeutics | Series B | 53.2M |
| 2/2022 | Terray Therapeutics | Series A | 0 |
| 7/2022 | Xilis | Series A | 0 |
| 6/2021 | RayzeBio | Series C | 108M |
| 6/2018 | Skyhawk Therapeutics | Venture Round | 0 |
| 3/2020 | Silverback Therapeutics | Series B | 0 |
| 4/2021 | Boundless Bio | Series B | 105M |
| 4/2020 | MOMA Therapeutics | Series A | 86M |
| 5/2023 | Boundless Bio | Series C | 0 |
| 9/2018 | System1 Biosciences | Series A | 25M |
| 11/2022 | Rezo | Series A | 0 |
| 6/2019 | BlackThorn Therapeutics | Series B | 76M |
| 1/2021 | Vera Therapeutics | Series C | 0 |
| 3/2021 | Insitro | Series C | 400M |
| 2/2019 | Maze Therapeutics | Series A | 191M |
| 11/2021 | Antiva Biosciences | Series D | 0 |
| 3/2023 | Chroma Medicine | Series B | 0 |
| 11/2018 | NextCure | Series B | 93M |
| 7/2022 | Ozette Technologies | Series A | 0 |
| 7/2022 | Cartography Biosciences | Series A | 0 |
| 7/2022 | Xilis | Series A | 0 |
| 6/2022 | DEM BioPharma | Series A | 0 |
| 6/2022 | Dren Bio | Series B | 0 |
| 5/2022 | Pleno | Seed Round | 0 |
| 5/2022 | Remix Therapeutics | Series B | 0 |
| 5/2022 | MOMA Therapeutics | Series B | 0 |
| 5/2022 | Aspen Neuroscience | Series B | 0 |
| 4/2022 | Pheast Therapeutics | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
